View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. AIM
9 May 2022

AIM Announces Its Acquisition by Blue Matter, a Leading Strategic Consultancy Focused on the Life Sciences

AIM is pleased to announce that it has been acquired by Blue Matter, a leading strategic consulting firm specializing in the life science industry.  AIM will continue to operate under its own name and maintain its identity as a leading specialist in life science supply chains.  The new arrangement is expected to provide strategic and mutual benefits to both AIM and Blue Matter.

AIM will provide a strategic complement to Blue Matter’s offerings and enhance its PathfinderSM suite of capabilities, which are designed to help biopharma companies enter European markets and succeed.  According to George Schmidt, Blue Matter Managing Partner in London, “We typically lead strategy work, but clients often have specialized needs when it comes to establishing operations in Europe, such as building and running flawless supply chains. AIM directly addresses that need.”

AIM’s founder, Richard de Bakker added, “Blue Matter and AIM have a long, positive relationship. We often serve the same clients, with needs that intersect the capabilities of both firms. By joining forces, we can boost the value of each firm while providing enhanced services to clients. It will also provide additional opportunities for AIM’s consulting team.”

Blue Matter’s proximity to emerging companies in the US will allow AIM to engage with them earlier, as they decide whether and how to enter Europe. AIM will continue providing consultancy and interim management services to pharmaceutical companies in Europe and elsewhere.

The acquisition was finalized on December 31, 2020.

Recently, AIM hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU